CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 141 enrolled
Drug / intervention
Femostondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02726971
NCT02726971Phase 2Completed
CompareCT.gov

A Prospective, Randomized, Controlled Trial Comparing 2 Different Doses of Estrogen Therapy After Hysteroscopic Adhesiolysis as an Adjuvant to Prevent Recurrence of Intrauterine Adhesions

Fu Xing Hospital, Capital Medical University·interventional·Posted Apr 4, 2016·Updated Apr 10, 2017

In Brief

A Phase 2 clinical trial evaluating Femoston for Asherman Syndrome. Completed, enrolled 141 participants across 1 site.

Detailed Summary

This single-center,prospective,randomized,controlled trial is conducted to evaluate the efficacy of different doses of estrogen artificial periodic therapy after hysteroscopic adhesiolysis in patients with moderate-severe adhesion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsherman Syndrome
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 4, 2016
Enrollment StartApr 1, 2016
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.2 years ago

Interventions

Femostondrug

Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.